Nootropic Peptides

For laboratory and research use only — not for human consumption. All content is educational.
Mechanism hub

NGF-inducing peptides

Nerve growth factor (NGF) is BDNF's older cousin. It sits alongside BDNF in the neurotrophin family, uses a related receptor system (TrkA rather than TrkB), and is particularly critical to the survival and function of cholinergic neurons in the basal forebrain — the same neuronal population that degenerates preferentially in Alzheimer's disease. Peptides that induce NGF as well as BDNF have a distinctive cognitive-relevance profile that the pure-BDNF-inducer family does not.

The molecular difference

NGF versus BDNF — the same family, different targets

NGF and BDNF are both members of the neurotrophin family — small secreted proteins that support the survival, development, and function of specific neuronal populations. They share a common evolutionary origin and a common receptor-family architecture, but they target different neurons and support different aspects of cognitive function.

BDNF binds TrkB receptors that are widely expressed across the hippocampus and cortex. It supports activity-dependent synaptic plasticity — the cellular substrate of learning and memory. This is why the BDNF-induction endpoint dominates the cognitive-enhancement peptide literature.

NGF binds TrkA receptors that are highly enriched on cholinergic neurons in the basal forebrain. Cholinergic tone supports attention, arousal, and the general cognitive-context state that memory operates within. Cholinergic-neuron degeneration is one of the earliest and most severe pathologies of Alzheimer's disease, which is why the cholinergic hypothesis of AD dominated the field for decades. Peptides that induce NGF specifically — Semax, Selank, Noopept, Cerebrolysin, N-Acetyl Semax — engage this distinctive cholinergic-support angle.

The family

Peptides that induce NGF

Why this cluster matters

The cholinergic-support angle

Alzheimer's disease research

The cholinergic hypothesis of Alzheimer's disease — the observation that basal forebrain cholinergic neurons degenerate early and severely in AD, and that cholinesterase-inhibitor drugs produce measurable if modest cognitive benefit — motivates a distinctive research angle for NGF-inducing peptides. Peptides that support cholinergic-neuron survival attack the same underlying pathology as cholinesterase inhibitors but from a different mechanistic direction.

Attention and arousal research

Cholinergic tone modulates attention, arousal, and cognitive flexibility. Peptides that support cholinergic function have a distinctive positioning for research designs probing sustained attention, focus, or cognitive flexibility under load — endpoints where BDNF-induction alone (via the hippocampal memory-consolidation route) is less directly relevant.

Ischaemic-injury research

Cholinergic neurons are relatively resistant to some forms of ischaemic injury but vulnerable to others. Peptides that support cholinergic survival provide a trophic-support angle for stroke and post-ischaemic cognitive-recovery research that complements the direct anti-apoptotic and antioxidant mechanisms.

Combination with BDNF-inducers

The peptides in this cluster typically induce BDNF and NGF together — Semax raises both, Selank raises both (though more modestly), Noopept raises both. This combination profile is why the family is more clinically-relevant than a hypothetical BDNF-only or NGF-only inducer: it covers both the synaptic-plasticity (BDNF) and cholinergic-support (NGF) arms of the cognitive-relevance space.